Search

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Innovations in ophthalmology: what can the innovations of the past teach us about tomorrow?

BUOS Prize Essay – 2nd prize winner for 2013 submissions Introduction An essay titled Innovations in Ophthalmology might choose to focus on the history; from cataract couching to femtosecond lasers, ophthalmology has had no shortage of topics worthy of discussion....

The ‘theatre of the mind’: Charles Bonnet Syndrome and Esme’s Umbrella

The founder of Esme’s Umbrella shares her experience with the poorly understood condition Charles Bonnet Syndrome and the creation of the campaign. Many years ago, when I was a young actress, I was in an American play called ‘Butterflies are...

EU: is it time to leave and embrace the world?

Should the United Kingdom remain a member of the European Union (EU) or leave? It’s a big decision involving some complex issues, and there’s no doubt the EU will continue to change. Ipsos MORI’s monthly EU voting intention poll published...

Redeployment during the COVID-19 pandemic: personal accounts from four ophthalmology trainees

We once believed that the coronavirus would not penetrate the safe confines of the United Kingdom, like so many outbreaks before this. Once the news came that this pandemic descended into our hospitals, the anxieties about redeployment began. Many of...

In conversation with Charles Leclercq (ARxVision)

Julian Jackson (Founder and Director, VisionBridge) spoke to Charles Leclercq (CEO, ARx) about the ARxVision, a wearable device that captures the world around us through audio and artificial intelligence to empower blind and low-vision individuals. You can read the Eye...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...